Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor

Abstract Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) receptor (Erenumab) or against CGRP (Eptinezumab, Fremanezumab, Galcanezumab) are new substances for the preventive treatment of migraine. They represent an extension of the therapeutic options, which already exist in...

Full description

Bibliographic Details
Main Authors: Hans-Christoph Diener, Stefanie Förderreuther, Charly Gaul, Florian Giese, Till Hamann, Dagny Holle-Lee, Tim P. Jürgens, Katharina Kamm, Torsten Kraya, Christian Lampl, Arne May, Uwe Reuter, Armin Scheffler, Peer Tfelt-Hansen
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Neurological Research and Practice
Subjects:
Episodic migraine
Chronic migraine
Migraine prevention
CGRP
Monoclonal antibodies
Guideline
Online Access:http://link.springer.com/article/10.1186/s42466-020-00057-1

Internet

http://link.springer.com/article/10.1186/s42466-020-00057-1

Similar Items